Abstract 4801
Background
X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1) is a tumor suppressor that is frequently lost or down-regulated by aberrant promoter hypermethylation in multiple human cancers. To explore XAF1’s candidacy for a suppressor in breast tumorigenesis, we investigated its expression status in tumor cell lines and tissues, effect on ER regulation of cell growth, and the molecular basis for its function.
Methods
XAF1 expression was examined by RT-PCR, immunoblot and bisulfite sequencing. Molecular basis for the XAF1 interplay with ERa and BRCA1 was defined using gene transfection, siRNA-mediated depletion, immunoprecipitation, pull-down assays, ubiquitination assay, immunohistochemistry and animal studies.
Results
XAF1 expression was lost or abnormally diminished by promoter hypermethylation in a substantial fraction of cell lines and primary tumors. XAF1 expression shows an inverse correlation with ERα expression. In ERα-expressing cells, restoration of XAF1 expression extremely increased cellular sensitivity to estrogen-induced, ERα-mediated apoptosis. Likewise, in ERα-nonexpressing cells, recovery of ERα restoration led to the recovery of apoptotic response to estrogen in XAF1-dependent fashion. Intriguingly, XAF1 was found to directly bind to and destabilizes ERα and this interaction is crucial for its apoptosis-promoting activity. Mechanistically, XAF1 has the characteristic of binding with E3 ligase, XAF1 interacts with BRCA1 and subsequently stimulates BRCA1 binding to ERα and BRCA1-mediated K48 polyubiquitination of ERα. Using a series of truncated mutants, we determined the domains of XAF1, ERα, and BRCA1 that are required for the assembly formation. Additionally, XAF1 was characterized to be upregulated by estrogen at the transcription level through the p38, JNK, and NF-kB signaling pathway.
Conclusions
XAF1 is promoted by estrogen and its activation directs the apoptotic switch of estrogen function through the assembly of BRCA1-mediated ERα destruction complex. Our study illuminates the mechanistic consequence of epigenetic inactivation of XAF1 in human breast tumorigenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sung-Gil Chi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract